Times13 Nov 2020 09:14
Brief mention in the Times today Re the Lancet. Mentions company by name ‘...their findings served as proof that SNG001, a drug developed by Synairgen, a biotech firm in Southampton, could help C19 patients recover. But they added that more research was needed.’
Very small article on page 11. Sadly no mention of phase 3, or zero analysis of the difference this could make at home, in care homes or to the NHS.